- Home
- RFL vs ICCM Comparison
RFL vs ICCM Comparison
Compare RFL & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFL
- ICCM
- Stock Information
- Founded
- RFL 2017
- ICCM 2006
- Country
- RFL United States
- ICCM Israel
- Employees
- RFL N/A
- ICCM N/A
- Industry
- RFL Real Estate
- ICCM
- Sector
- RFL Finance
- ICCM
- Exchange
- RFL Nasdaq
- ICCM Nasdaq
- Market Cap
- RFL 48.4M
- ICCM 55.8M
- IPO Year
- RFL N/A
- ICCM N/A
- Fundamental
- Price
- RFL $1.93
- ICCM $1.01
- Analyst Decision
- RFL
- ICCM Strong Buy
- Analyst Count
- RFL 0
- ICCM 1
- Target Price
- RFL N/A
- ICCM $2.50
- AVG Volume (30 Days)
- RFL 462.2K
- ICCM 287.1K
- Earning Date
- RFL 06-11-2025
- ICCM 08-19-2025
- Dividend Yield
- RFL N/A
- ICCM N/A
- EPS Growth
- RFL N/A
- ICCM N/A
- EPS
- RFL N/A
- ICCM N/A
- Revenue
- RFL $732,000.00
- ICCM $3,273,000.00
- Revenue This Year
- RFL N/A
- ICCM $83.41
- Revenue Next Year
- RFL N/A
- ICCM $185.02
- P/E Ratio
- RFL N/A
- ICCM N/A
- Revenue Growth
- RFL 35.56
- ICCM 0.34
- 52 Week Low
- RFL $1.27
- ICCM $0.48
- 52 Week High
- RFL $3.19
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- RFL 51.93
- ICCM 45.31
- Support Level
- RFL $1.56
- ICCM $0.81
- Resistance Level
- RFL $1.84
- ICCM $1.03
- Average True Range (ATR)
- RFL 0.20
- ICCM 0.06
- MACD
- RFL -0.03
- ICCM 0.01
- Stochastic Oscillator
- RFL 28.68
- ICCM 71.83
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.